GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.
Uenishi GI, Repic M, Yam JY, Landuyt A, Saikumar-Lakshmi P, Guo T, Zarin P, Sassone-Corsi M, Chicoine A, Kellogg H, Hunt M, Drow T, Tewari R, Cook PJ, Yang SJ, Cerosaletti K, Schweinoch D, Guiastrennec B, James E, Patel C, Chen TF, Buckner JH, Rawlings DJ, Wickham TJ, Mueller KT.
Uenishi GI, et al. Among authors: rawlings dj.
JCI Insight. 2024 Feb 8;9(6):e171844. doi: 10.1172/jci.insight.171844.
JCI Insight. 2024.
PMID: 38516892
Free PMC article.